Monthly Archives: September 2008
Icahn to BMS: Offer is Inadequate
In a statement to the press today, ImClone Chairman Carl Icahn said that the review committee overlooking Bristol-Myers Squibb’s offer to purchase the biotech company for $60 per share $4.5 billion just isn’t good enough.
He not only accused BMS of lowballing, but also admitted that the company has been in talks with the head of [...]
Posted in Biotech, Deals, Strategy Tagged BMS, Bristol-Meyers Squibb, Carl Icahn, Deal, Erbitux, ImClone, negotiation, Pharma, sale 1 Comment

King Ups Alpharma Offer